Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Elicio Therapeutics (9HA) Stock Price & Analysis

0 Followers

9HA Stock Chart & Stats

€1.38€0.00(-1.43%)
At close: 5:30 PM GMT+1
€1.75€2€2.25€2.5Jul 29Sep 18
Day’s Range
EUR 1.26 - EUR 1.38
52-Week Range
EUR 1.26 - EUR 12.40
Previous Close
EUR 1.40
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 40.81M
Enterprise Value
EUR 30.94M
Total Cash (Recent Filing)
EUR 30.90M
Total Debt (Recent Filing)
EUR 6.83M
Price to Earnings (P/E)
―
Beta
-0.60
Next Earnings
Mar 26, 2027 (Est.)
EPS Estimate
-0.34
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

AMP Immunotherapy Platform

Elicio’s lymph node-targeting AMP platform provides a defined technological approach across its cancer vaccine and immunotherapy pipeline. If clinical studies validate the intended immune response, the platform could support multiple oncology programs rather than relying on a single candidate.

Improved Balance Sheet

The substantial improvement from negative equity and high debt in 2024 to positive TTM equity and lower debt strengthens near-term financial flexibility. This repair does not remove funding risk, but it gives Elicio a more manageable capital structure while advancing its clinical pipeline.

Reduced Net Losses

The reduction in annualized losses indicates some improvement from the company’s deepest reported loss period. Although Elicio remains far from profitability, a lower loss burden could extend financial resources or reduce the pace of capital required as development programs continue.

Bears Say

No Commercial Revenue

Elicio has not yet established meaningful commercial revenue, confirming that its business remains dependent on clinical development rather than product sales. Without an operating revenue base, future progress and corporate funding capacity remain tied to pipeline advancement and external capital.

Persistent Cash Burn

Heavy and continuing cash consumption means the company is not self-funding its operations or clinical programs. Sustained negative operating and free cash flow can require additional financing, potentially limiting strategic flexibility and increasing dilution or funding pressure over the next several quarters.

Capital Structure Volatility

The sharp change in leverage across reporting periods shows that Elicio’s capital structure remains volatile despite recent repair. Continued large losses could weaken equity again, creating renewed balance-sheet stress and increasing the likelihood that further funding will be needed.

Elicio Therapeutics News

9HA FAQ

What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was €1.26 and its highest was €12.40 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is €40.81M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s next earnings report is estimated for Mar 26, 2027 (not yet confirmed), which is in 135 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Nov 05, 2026. The company reported -€0.269 earnings per share for the quarter, beating the consensus estimate of -€0.43 by €0.161.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 28,307,224 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -€0.269 in its last earnings report, beating expectations of -€0.43. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in DE:9HA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology